Acute Effects of Aerosolized Iloprost in COPD Related Pulmonary Hypertension - A Randomized Controlled Crossover Trial
Open Access
- 27 December 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12) , e52248
Abstract
Inhaled iloprost potentially improves hemodynamics and gas exchange in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension (PH). To evaluate acute effects of aerosolized iloprost in patients with COPD-associated PH. A randomized, double blind, crossover study was conducted in 16 COPD patients with invasively confirmed PH in a single tertiary care center. Each patient received a single dose of 10 µg iloprost (low dose), 20 µg iloprost (high dose) and placebo during distinct study-visits. The primary end-point of the study was exercise capacity as assessed by the six minute walking distance. Both iloprost doses failed to improve six-minute walking distance (p = 0.36). Low dose iloprost (estimated difference of the means −1.0%, p = 0.035) as well as high dose iloprost (−2.2%, p<0.001) significantly impaired oxygenation at rest. Peak oxygen consumption and carbon dioxide production differed significantly over the three study days (p = 0.002 and p = 0.003, accordingly). As compared to placebo, low dose iloprost was associated with reduced peak oxygen consumption (−76 ml/min, p = 0.002), elevated partial pressure of carbon dioxide (0.27 kPa, p = 0.040) and impaired ventilation during exercise (−3.0l/min, p<0.001). Improvement of the exercise capacity after iloprost inhalation in patients with COPD-associated mild to moderate PH is very unlikely. Controlled-Trials.com ISRCTN61661881Keywords
This publication has 38 references indexed in Scilit:
- Six-Minute Walk Test Enhanced by Mobile Telemetric Cardiopulmonary MonitoringRespiration, 2010
- Percent Emphysema, Airflow Obstruction, and Impaired Left Ventricular FillingNew England Journal of Medicine, 2010
- Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2009
- Impact of Pulmonary Artery Pressure on Exercise Function in Severe COPDChest, 2009
- Last Word on Point:Counterpoint: The major limitation to exercise performance in COPD is 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflationJournal of Applied Physiology, 2008
- A randomised, controlled trial of bosentan in severe COPDEuropean Respiratory Journal, 2008
- Prostacyclin Synthase in Smoking-related Lung DiseaseProceedings of the American Thoracic Society, 2006
- Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary HypertensionCerebrovascular Diseases, 2006
- Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPDThorax, 2003
- Inhibition of Hypoxic Pulmonary Vasoconstriction by NifedipineNew England Journal of Medicine, 1981